Research programme: alpha-2 macroglobulin therapeutics - Cytonics

Drug Profile

Research programme: alpha-2 macroglobulin therapeutics - Cytonics

Alternative Names: A2M - Cytonics; Recombinant A2M - Cytonics; α-2 macroglobulin - Cytonics; α2M - Cytonics

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytonics Corporation
  • Class Proteins
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Osteoarthritis

Highest Development Phases

  • Preclinical Diabetic foot ulcer
  • No development reported Osteoarthritis

Most Recent Events

  • 28 Aug 2018 No recent reports of development identified for preclinical development in Osteoarthritis in USA (Intra-articular)
  • 17 Mar 2015 Preclinical trials in Diabetic foot ulcer in USA (unspecified route) prior to March 2015
  • 26 Jul 2014 Research programme: alpha-2 macroglobulin - Cytonics is available for licensing as of 26 Jul 2014. http://www.cytonics.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top